Daniel Chao

Daniel Chao is an experienced executive in the biotechnology and therapeutic sectors, currently serving as Operating Partner at Palo Santo since August 2023. Previously, Daniel held the position of Senior Advisor to the CEO at iBio, Inc., where leadership was supported in business integration and strategic initiatives. As Chief Business Officer at Rubryc Therapeutics, Daniel oversaw deal assessment, due diligence, and negotiation efforts. Daniel's leadership at Herophilus as CEO contributed to the company’s productivity during the pandemic. Co-founding Halo Neuroscience led to significant capital raises exceeding $30 million, while advisory roles at Brigham and Women's Hospital focused on scientific strategy. Daniel's early career includes key positions at NeuroPace, Inc., McKinsey & Company, and Palo Alto Investors. Daniel holds an MD and MS in Neuroscience from Stanford University and a BA in Biochemistry from the University of California, Berkeley.